קישור לכתבות בעיברית בתחתית העמוד
Cell Cure Neurosciences’ Shareholders Will Invest $7.1 M in the Company’s Development of Innovative Stem Cell Treatments for Neural and Retinal Diseases.
Cell Cure announced a $7.1 million equity investment from its existing shareholders, BioTime, Teva Pharmaceutical Industries Ltd. and Hadasit Bio-Holdings. The equity investment will enable Cell Cure to continue development of OpRegen™ for the treatment of AMD and development of human embryonic stem cell-based therapies for neural degenerative disorders.
Cell Cure Neuroscience Ltd, a Subsidiary of BioTime, Inc. and Hadasit Bio Holdings Ltd., Enters Into An Exclusive License Option Agreement With Teva Pharmaceutical Industries Ltd., to Develop and Market OpRegen™ for the Treatment of Age-Related Macular Degeneration.
Cell Cure and Hadasit Bio Holdings have entered into an exclusive license option agreement with Teva Pharmaceutical Industries to develop and commercialize Cell Cure's OpRegen™ product for the treatment of AMD. Subject to the terms of the agreement, if Teva exercises its option to obtain an exclusive license to OpRegen™, Teva will have responsibility for funding clinical trials from that point on, obtaining regulatory approvals, and marketing the product.